Multicomponent Composites for Bioengineering of Dental Bone Tissue
Multicomponent Composites for Bioengineering of Dental Bone Tissue
批准号:
8684259
负责人:
Amol Vijay Janorkar
金额:
$11.44万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-02-20 至 2016-01-31
关键词:
AdhesionsAgeAntibioticsBacterial InfectionsBehaviorBiochemicalBiocompatibleBiocompatible MaterialsBioglassBioglass 45S5BiologicalBiomedical EngineeringBiomedical TechnologyBone Morphogenetic ProteinsBone RegenerationBone TissueCell SurvivalCell physiologyCeramicsCharacteristicsCollagenCytoskeletonDataDefectDentalDental ImplantsDentistryDevelopmentDoxycyclineDrug Delivery SystemsEdentulous MouthElastinElectron MicroscopyEngineeringEnvironmentExcisionExhibitsFutureGenetic EngineeringGrowthGrowth FactorHealedHealthInfectionInfiltrationInflammationInvestigationLeadMatrix Metalloproteinase InhibitorMeasuresMechanicsMembraneMethodologyModelingMorbidity - disease rateOperative Surgical ProceduresOralOsteoblastsOsteogenesisPatientsPharmaceutical PreparationsPhase TransitionPolymersPopulationProcessPropertyProteinsQuality of lifeResearchSiteSolutionsStimulusStructureSurfaceSystemTechniquesTemperatureTensile StrengthTestingTissue EngineeringTissuesTooth ExtractionTooth LossTooth structureTraumaWorkbasebiomaterial compatibilitybonecontrolled releasedesignhealingimprovedinnovationmaxillofacialmembrane activitymineralizationnovelpolypeptiderecombinant human bone morphogenetic protein-2reconstructionresponsesoft tissuetissue culturetumortwo-dimensional
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Maxillofacial bony defects, occurring as a result of tumor resection, infection, trauma, as well as tooth loss or extraction, are often associated with patient morbidity. Development of suitable biomaterials for reconstruction of oral structures through guided bone regeneration (GBR) has reduced morbidity, improved quality of life after surgery, and has benefitted partially or completely edentulous patients by supporting dental implants used to replace the lost teeth. The GBR techniques primarily use a polymeric barrier membrane to stop infiltration of surrounding undesired soft tissue into the defect site and support new bone formation. Currently available barrier membranes display significant shortfalls. For example, the non- bioresorbable membranes need a second surgery for their removal after tissue healing. The synthetic, bioresorbable membranes eliminate this need for the second surgery and provide sufficient mechanical strength but they lead to local inflammation during degradation. The natural, bioresorbable membranes (primarily collagen) eliminate inflammation, but still suffer from rapid degradation and inadequate mechanical strength. More importantly, none of these membranes offer a tunable release of bioactive agents (osteoinductive proteins, growth factors, antibiotics) to enhance the new bone tissue formation. Therefore, it is desirable to have a biomaterial with suitable biocompatibility, mechanical properties, and bioactive agent release. We propose to prepare novel multi-component composite membranes that incorporate a stimulus- responsive smart polymer (elastin-like polypeptide, ELP), biodegradable ceramic (45S5 Bioglass), and collagen as network former. The major component, ELP, is genetically engineered to provide precise control of its properties and exhibits an inverse phase transition behavior in response to changes in its solution environment. We hypothesize that incorporation of ELP and Bioglass will improve the mechanical properties of the membranes, while the inverse phase transition behavior of ELP will control the release rates of bioactive agents from the membranes. This research is divided into following key Specific Aims: (1) Create and Characterize ELP-Bioglass-Collagen Membranes; (2) Characterize Drug Release Profiles for Composite Membranes; (3) Evaluate Drug-loaded ELP-Bioglass-Collagen Membranes for Osteoblast Culture. Our research will significantly impact major technological and biological problems that currently limit the development of barrier membranes for simultaneous drug delivery and tissue engineering in GBR and help achieve: (1) sustained release of bioactive agents; (2) improved bone tissue growth; and (3) reduced post- surgical bacterial infections and infiltration of surrounding undesired soft tissue. While advancing the fundamental understanding of extra-cellular matrix-based composites, our research will provide new composite materials for GBR and other applications requiring bone replacement. Thus, the new ELP- Bioglass-Collagen materials may directly impact biomedical technology in the near future.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
3D Spheroid Model of Adipose Pathophysiology
-
批准号:9177098
-
项目类别:
-
资助金额:$35.53万
-
财政年份:2016
-
负责人:Amol Vijay Janorkar
-
依托单位:
Multicomponent Composites for Bioengineering of Dental Bone Tissue
-
批准号:8810667
-
项目类别:
-
资助金额:$11.44万
-
财政年份:2014
-
负责人:Amol Vijay Janorkar
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: